Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]
SEC Accession No. 0002052113-25-002218
Filing Date
2025-07-15
Accepted
2025-07-15 17:12:36
Documents
3

Document Format Files

Seq Description Document Type Size
1 primary_doc.html SCHEDULE 13G/A  
1 primary_doc.xml SCHEDULE 13G/A 5714
2 EXHIBIT 24: POWER OF ATTORNEY PowerOfAttorney.txt EX-24 2924
3 EXHIBIT 99: ITEM 7 Item_7.txt EX-99 496
  Complete submission text file 0002052113-25-002218.txt   10864
Mailing Address 45 WIGGINS AVENUE BEDFORD MA 01730
Business Address 45 WIGGINS AVENUE BEDFORD MA 01730 781-430-8200
Stoke Therapeutics, Inc. (Subject) CIK: 0001623526 (see all company filings)

EIN.: 471144582 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SCHEDULE 13G/A | Act: 34 | File No.: 005-91051 | Film No.: 251125556
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)

Mailing Address 50 HUDSON YARDS NEW YORK NY 10001
Business Address 50 HUDSON YARDS NEW YORK NY 10001 (212) 810-5800
BlackRock Portfolio Management LLC (Filed by) CIK: 0002052113 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SCHEDULE 13G/A